A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- RANDOMIZED · SEQUENTIAL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 66
- Population
- ALL · 50 Years to 90 Years
- Duration
- 2024-11-21 to 2031-06-30
- Intervention
- SAR402663; Diluent
- Comparator
- Not reported
- Outcomes measured
- Incidence and severity of ocular treatment emergent adverse event (TEAEs) — Day 1 to Week 52; Incidence and severity of ocular treatment emergent serious adverse event (TESAEs) — Day 1 to Week 52; Incidence and severity of non-ocular TEAEs — Day 1 to Week 52; Incidence and severity of non-ocular TESAEs — Day 1 to Week 52; Number of participants with any clinically significant changes in laboratory variables — Day 1 to Week 52; Number of participants with any clinically significant changes in vital signs — Day 1 to Week 52; Percentage of participants not requiring supplemental anti- vascular endothelial growth factor (VEGF) therapy — Day 1 t…; Annualized injection rates of anti-VEGF therapy — Day 1 to Week 52; Change from baseline in BCVA using the ETDRS letter score — Baseline, Week 52; Percentage of participants not losing more than or equal to 15 ETDRS letters from baseline — Baseline, Week 52; Change from baseline in central subfield thickness (CST), measured by spectral domain optical coherence tomography (SD-…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.